Last reviewed · How we verify
NCT05512780
Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer
Phase 2 trial testing Dalpiciclib in Solid Tumor in 30 participants. Status unknown.
10 August 2023
Quick facts
| Lead sponsor | Hebei Medical University Fourth Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 10 September 2022 |
| Primary completion | 10 August 2023 |
| Estimated completion | 10 August 2024 |
Drugs / interventions tested
- Dalpiciclib — full drug profile →
Conditions studied
- Solid Tumor — all drugs for Solid Tumor →
Sponsor
Hebei Medical University Fourth Hospital
Who can join
Adults 18 to 75, female only, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, open-label, exploratory clinical study
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05512780
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dalpiciclib
Trials testing the same drug.
- NCT07207070 — A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined Wit · Phase 3 · recruiting
- NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
- NCT07492394 — Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer · Phase 2 · recruiting
- NCT07179939 — Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study · Phase 2 · not yet recruiting
- NCT06650748 — Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With o · Phase 2 · enrolling by invitation
Other recruiting trials for Solid Tumor
Currently open trials in the same condition.
- NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
- NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting
Other Hebei Medical University Fourth Hospital trials
Trials by the same sponsor.
- NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br · Phase 2 · not yet recruiting
- NCT07448077 — Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC · Phase 2 · not yet recruiting
- NCT07410611 — ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy · Phase 2 · not yet recruiting
- NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting
- NCT07492394 — Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05512780 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hebei Medical University Fourth Hospital
- Last refreshed: 23 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05512780.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing